MNOV: Encouraging Interim Analysis for Phase 2b/3 ALS Trial
On December 5, 2024, MediciNova, Inc. (MNOV) announced a study update and interim analysis from the Phase 2b/3 COMBAT-ALS trial were scheduled to...
202 Views
MNOV: Monetary Damages Due Following Sanofi/Novartis Patent Dispute Settlement
On November 11, 2024, MediciNova, Inc. (MNOV) announced that it was notified by Genzyme, a subsidiary of Sanofi, that the Sanofi/Novartis...
369 Views
MNOV: MN-166 to be Evaluated in NIH-Sponsored Expanded Access Trial in ALS
On September 30, 2024, MediciNova, Inc. (MNOV) announced that MN-166 (ibudilast) will be evaluated in a National Institutes of Health (NIH) -...
204 Views
MNOV: Phase 3 ALS Readout in 2025
On August 8, 2024, MediciNova, Inc. (MNOV) filed form 10-Q with financial results for the second quarter of 2024. The company is conducting a...
323 Views
MNOV: Multiple Abstracts Presented at 92nd EAS Congress
On May 28, 2024, MediciNova, Inc. (MNOV) announced that two abstracts regarding MN-001 (tipelukast) and MN-002 were presented as posters at the...
242 Views